Biopharmaceutical giant Gilead Sciences Inc. (GILD) finds, develops, and commercializes medicines for unmet medical needs in the United States, Europe, and other countries. The stock has gained 12.1% over the past six months and 3.5% over the past month to close its last trading session at $65.
The company reported impressive sales in the last reported quarter. GILD’s total product sales, excluding Veklury, increased 7% year-over-year to $5.69 billion for the second quarter ended June 30, 2022. Furthermore, its HIV product sales increased by 7% from the prior-year quarter to $4.23 billion. Oncology sales for the company reached $527 million, representing a year-over-year increase of 71%.
